Ferring and Blackstone jointly invest in a new bladder cancer therapy
Category: #health  By Pankaj Singh  Date: 2019-11-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ferring and Blackstone jointly invest in a new  bladder cancer therapy

Private investment firm, Blackstone Life Sciences and Ferring Pharmaceuticals recently announced joint investment of more than USD 570 million in a novel investigational  gene therapy, rAd-IFN/Syn3 (nadofaragene firadenovec). The therapy is being developed for the treatment of patients with high-grade BCG (Bacillus Calmette-Guérin) unresponsive and NMIBC (non-muscle invasive bladder cancer).

Ferring has created a new gene therapy company and Ferring subsidiary, FerGene to potentially commercialize rAd-IFN/Syn3 in the U.S. and to advance the global clinical development. FerGene’s aim is to acquaint patient population with this promising therapy. Ferring will invest up to USD 170 million and Blackstone will invest USD 400 million in FerGene. Ferring is also expected to potentially launch & commercialize rAd-IFN/Syn3 outside of the U.S.

Currently in late Phase 3 development, rAd-IFN/Syn3 has been granted Breakthrough Therapy designation and had its Biologics License Application  accepted for filing and granted Priority Review by the Food and Drug Administration.

Frederik Paulsen, Chairman of Ferring Pharmaceuticals, was reportedly quoted saying that it requires dedicated focus and capabilities to bring a novel gene therapy to the market. FerGene, will aid Ferring Pharmaceuticals with the resources & team needed to potentially bring rAd-IFN/Syn3 to patients.

Paulsen added that through this new joint financing model between Blackstone Life Sciences and Ferring, the company aims to ensure that more and more people with high-grade, Bacillus Calmette-Guérin unresponsive, non-muscle invasive bladder cancer may benefit from this novel gene therapy, if it is approved.

Phase 3 clinical trial results for nadofaragene firadenovec will be presented at the SUO (Society of Urologic Oncology) 20th Annual Meet in Washington, DC. FerGene will hold the marketing authorization of nadofaragene firadenovec, upon the potential FDA approval.

Dr. Stephen A. Boorjian, Professor of Urology at Mayo Clinic in Rochester and the Coordinating Investigator for the trial was reported to state that this trial expands the potential for search of effective alternatives to cystectomy for patients with high-grade, Bacillus Calmette-Guérin unresponsive, non-muscle invasive bladder cancer, which can significantly improve patient care in future.
 

Source Credit: https://www.blackstone.com/media/press-releases/article/ferring-and-blackstone-life-sciences-invest-over-$570-million-usd-in-novel-gene-therapy-for-bladder-cancer-patients



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...